Background
==========

Antimicrobial agents are important drugs for the treatment of bacterial infections in pigs. Because of intensive pig rearing in Europe, large numbers of pigs are treated annually. However, the specific bacterial aetiology and the antimicrobial susceptibility of the bacteria are only determined in a limited number of cases irrespectively of country. During acute infections it is important to use an effective antimicrobial treatment as early as possible. Often treatment is initiated before or even without subsequent bacteriological examination of diseased pigs. For some bacterial species the susceptibility data are available, whereas for other species, the susceptibility pattern varies or is unknown. Therefore the empirical treatment has to be based mostly on a general knowledge regarding the successful usage of certain drugs on the farm in question.

The introduction of indicator organisms in baseline monitoring studies has resulted in knowledge on existing resistance genes reservoirs, which potentially can be transferred to pathogenic bacteria. The resistance among indicator bacteria reflects a certain selective pressure caused by the general use of antimicrobials in animal production and the adaptation of these bacteria to the new conditions. That means on a global view that there is a selection of the fittest microorganisms based on the presence of resistance determinants and their stable inheritance. There are only a few internationally reported studies on the occurrence of antimicrobial resistance in bacteria causing infections in food animals in Europe.

To compensate for this, the ARBAO-II-project was funded by the European Union (FAIR5-QLK2-2002-01146). This study was funded for the period 2003--05 with the aim to establish a continuous monitoring of antimicrobial susceptibility of pathogenic and indicator bacteria isolated from food animals at 19 veterinary laboratories in 18 European countries. Most of the laboratories use validated and harmonised methodologies. In this report the first data on the occurrence of antimicrobial resistance among bacteria causing infections in pigs are reported.

Methods
=======

Participating laboratories
--------------------------

Each year the laboratories participating in the project were requested to fill in excel-file templates with national summary data on the occurrence of antimicrobial resistance from different bacterial species and groups. The participants were asked to submit national data but if this was not possible they were advised to submit regional or institutional data as done by England, including Wales. The data for some countries were incomplete e.g. for Austria and Latvia and data was deducted for others if the number of isolates were lower than 31.

Quality control
---------------

Invitation was announced annually through the network by email or facsimile to all ARBAO members to participate in self-evaluating proficiency tests (EQAS external quality assurance system) for antimicrobial susceptibility testing. The tests were conducted each year to test if the current methodologies were accurate, adequate and reliable \[[@B1],[@B2]\]. In addition, the EQAS served as a tool to pin out the laboratories from where annual data were reliable. The goal was to have all laboratories to perform antimicrobial susceptibility testing with a maximum of 10% total deviations (minor, major, or very major deviations) and a maximum of 5% critical deviations (major or very major deviations).

Eight strains of each of the species *Staphylococcus aureus, Mannheimia haemolytica, Pasteurella multocida*, *Streptococcus dysgalactiae, Streptococcus uberis*and *Escherichia coli*were selected for each EQAS iteration. Strains were obtained from the bacterial strain collection at the National Food Institute, Technical University of Denmark. All strains were included in only one EQAS iteration. The strains were inoculated to agar stab cultures for shipping to the participating laboratories. Participating laboratories also received a lyophilised reference strain as a quality control strain for susceptibility testing (*E. coli*ATCC 25922; *Campylobacter jejuni*ATCC 33560; *Enterococcus faecalis*ATCC 29212, *S. aureus*ATCC 25923, and *S. aureus*ATCC 29213) in each EQAS shipment.

The laboratories were instructed to follow specified testing instructions; subculture the test strains and propagates the quality control strains prior to performing the susceptibility method routinely used by the laboratory. In addition, laboratories were advised to maintain the quality control strain for future proficiency tests. After completion of the susceptibility testing of the test strains and the quality control strain, the participating laboratories were instructed to record the obtained results using MIC values or zone-diameter in millimetres and categorize each of the tested strains as either \"resistant\" (R), \"intermediate\" (I) or \"susceptible\" (S) against each tested antimicrobial agent using the breakpoints routinely used in their laboratory. They were then asked to record the information on the participating laboratory record sheet.

After submitting results, participating laboratories received an individual report. The individual reports for the participating laboratories reported all deviations from the expected values and suggestions of how to either solve or investigate the problem. For the quality control strains, deviations were defined as values that exceeded the quality control range of the strain. Deviations of the antimicrobial susceptibility results were categorised as minor, major or very major. A minor deviation was defined as an intermediate strain that was classified as susceptible or resistant or vice versa (i.e. I ↔ S or I ↔ R). A major deviation was defined as a susceptible strain that was classified as resistant (i.e. S → R). A very major deviation was defined as a resistant strain that was classified as susceptible (i.e. R → S).

The overall performance and the results were between 85--100% correct. In general, the concordance between results for Gram-negative bacteria was good e.g. 93% in 2003 and 95% in 2004 for *E. coli*. Therefore the summary results for these species might be compared between countries generally.

Test methods
------------

Each laboratory reported annually, which methods were used for antimicrobial susceptibility testing. Laboratories in Austria, England (including Wales), France, Italy, Latvia and Poland used disc diffusion test, whereas Denmark, The Netherlands, Norway, Sweden and Switzerland used the broth micro dilution method by which minimal inhibition concentration (MIC) are determined. Spain and Finland used both MIC determination and disc diffusion, whereas Belgium used tablet diffusion. Portugal utilized a micro-broth dilution test -- the automated ATB susceptibility test strip <http://www.biomerieux-diagnostics.com>. The manufactures of discs and microtitre plates for broth microdilution differed between countries.

All countries reported the extent to which they followed the standards of the Clinical and Laboratory Standards Institute (CLSI), M31-A2, M7-A6 or M2-A8 \[[@B3]\]. Austria, England (including Wales), France, The Netherlands, Norway, Sweden and Switzerland reported that they did not use CLSI breakpoints as listed in the fifteenth international supplement M100-S15 to determine the antimicrobial susceptibility levels but a mixture of these and national established breakpoints. Despite the differences in used breakpoints all of the countries performed susceptibility testing within the EQAS QC threshold.

Results
=======

Susceptibility data were obtained from 17,642 bacterial isolates from 15 European countries over the three year period 2002--2004 (Table [1](#T1){ref-type="table"}). The national data on susceptibility testing of each species varied considerably, i.e. 24 isolates of *S. suis*were tested in Portugal while 1,442 isolates of infectious *E. coli*were tested in France. The bacterial species and their antimicrobial resistance are given in Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}.

###### 

Data on antimicrobial susceptibility submitted from the participating laboratories in the different European countries during a three year period.

  Bacterial species                                     *A. pleuropneumoniae*   *S. suis*   *E. coli (Infections)*   *E. coli (Indicator)*   Total                                                                                                                  
  ------------------------------------------ ---------- ----------------------- ----------- ------------------------ ----------------------- ---------- -------------- -------------- -------------- ------------ ------ ------ ----- -------------- -------------- --------------
  Country and number of bacterial isolates   A          \-                      \-          \-                       \-                      \-         \-             \-             \-             \-           \-     \-     217   \-             \-             217
                                             B          \-                      \-          \-                       \-                      \-         \-             61             100            137          146    \-     \-    207            100            137
                                             DK         480                     514         441                      \-                      557        \-             111            77             177          293    317    208   884            1,465          826
                                             E^b^       54                      46          43                       \-                      34         53             365            352            313          \-     \-     \-    419            432            409
                                             F^a^       118--157                1271--88    99--130                  92--210                 68--305    72--196        862--1,442     784--1,364     758--1 412   101    101    100   1,055--1,753   1,080--1,958   1,029--1,838
                                             FIN        \-                      \-          \-                       \-                      \-         \-             141            65             61           \-     \-     391   141            65             452
                                             I          \-                      \-          \-                       \-                      \-         \-             \-             \-             \-           \-     103    166   \-             103            166
                                             LV         \-                      \-          \-                       \-                      \-         \-             \-             31             \-           \-     \-     \-    \-             31             \-
                                             NL         \-                      190         \-                       \-                      762        \-             311            308            \-           149    155    296   460            1,415          296
                                             N          \-                      \-          \-                       \-                      \-         \-             39             \-             45           187    \-     125   226            \-             170
                                             PL         32                      \-          \-                       150                     151        111            \-             \-             \-           \-     \-     355   182            151            466
                                             P          \-                      \-          \-                       \-                      \-         24             33             45             44           \-     \-     \-    33             45             68
                                             ES         \-                      \-          \-                       \-                      \-         \-             77             154            169          289    285    183   366            439            352
                                             S          \-                      \-          \-                       \-                      \-         \-             340            45             386          \-     303    \-    \-             348            386
                                             CH         \-                      \-          \-                       \-                      \-         \-             \-             92             47           \-     \-     \-    \-             92             47
                                                                                                                                                                                                                                                                    
  Total no. of isolates                      685--723   877--938                583--614    242--360                 1,572--1,809            260--384   2,340--2,920   2,053--2,633   2,137--2,791   1,17         1,26   2,04                                       

-: No data available, ^a^Multicenter study. The isolates were tested for different panels of antimicrobial agents in the different centers. ^b^: Isolates from England included also Wales and have been collected by The Veterinary Laboratory Agency. The remaining part of the United Kingdom has separate laboratories.

A -- Austria; B -- Belgium, DK -- Denmark, E -- England including Wales; F -- France; FIN -- Finland; I -- Italy; LV -- Latvia; NL -- The Netherlands; N -- Norway; PL -- Poland; P -- Portugal; ES -- Spain; S -- Sweden; CH -- Switzerland

###### 

Occurrence of antimicrobial resistance among *Actinobacillus pleuropneumoniae*isolated from pigs in different European countries.

  Antimicrobial agent              Year   Country and prevalence of resistance                       
  -------------------------------- ------ -------------------------------------- ------ ------ ----- -----
  Ampicillin                       2002   0.0                                    4.0    1.3    \-    2.0
                                   2003   0.2                                    7.0    0.5    8.0   \-
                                   2004   0.0                                    2.0    0.8    \-    \-
                                                                                                     
  Amoxicillin -- Clavulanic acid   2002   \-                                     \-     0.0    \-    0.0
                                   2003   \-                                     \-     0.0    0.0   \-
                                   2004   \-                                     \-     0.0    \-    \-
                                                                                                     
  Ciprofloxacin                    2002   0.0                                    4.0    0.0    \-    1.0
                                   2003   0.0                                    0.0    0.0    \-    \-
                                   2004   1.5                                    0.0    0.0    \-    \-
                                                                                                     
  Florfenicol                      2002   \-                                     \-     0.0    \-    \-
                                   2003   0.0                                    \-     0.0    \-    \-
                                   2004   0.0                                    \-     0.0    \-    \-
                                                                                                     
  Tetracycline                     2002   16.0                                   22.0   11.0   \-    4.0
                                   2003   3.7                                    37.0   10.6   5.0   \-
                                   2004   5.7                                    28.0   4.7    \-    \-
                                                                                                     
  Trimethoprim -- Sulphonamide     2002   0.0                                    13.0   8.3    \-    8.0
                                   2003   0.0                                    46.0   8.0    1.0   \-
                                   2004   1.6                                    28.0   4.6    \-    \-

-: No data available. DK -- Denmark, E -- England including Wales; F -- France; NL -- The Netherlands; PL -- Poland.

###### 

Occurrence of antimicrobial resistance among *Streptococcus suis*isolated from pigs in different European countries.

  Antimicrobial agent            Year   Country and prevalence of resistance                                  
  ------------------------------ ------ -------------------------------------- ------ --------- ------ ------ -------
  Erythromycin                   2002   \-                                     \-     64.6      \-     \-     \-
                                 2003   29.1                                   36.0   52.9      35.0   \-     \-
                                 2004   \-                                     50.0   58.1      \-     30.6   75.0
                                                                                                              
  Gentamicin                     2002   \-                                     \-     0.0       \-     28.0   \-
                                 2003   \-                                     \-     0.0       \-     0.0    \-
                                 2004   \-                                     \-     0.0       \-     53.2   100.0
                                                                                                              
  Penicillin                     2002   \-                                     \-     0.0       \-     10.6   \-
                                 2003   0.9                                    0.0    0.0       0.0    7.9    \-
                                 2004   \-                                     0.0    0.0       \-     8.1    13.0
                                                                                                              
  Tetracycline                   2002   \-                                     \-     57.8^a^   \-     73.3   \-
                                 2003   52.2                                   68.0   56.7^a^   48.0   55.0   \-
                                 2004   \-                                     68.0   62.5^a^   \-     64.0   92.0
                                                                                                              
  Trimethoprim -- Sulphonamide   2002   \-                                     \-     22.4      \-     30.0   \-
                                 2003   51.5                                   3.0    15.5      8.0    16.6   \-
                                 2004   \-                                     8.0    13.3      \-     14.4   \-

-: No data available, ^a^: Doxycycline. DK -- Denmark, E -- England including Wales; F -- France; NL -- The Netherlands; PL -- Poland; P -- Portugal.

###### 

Occurrence of antimicrobial resistance among *Escherichia coli*isolated from diseased pigs in different European countries.

  Antimicrobial agent              Year   Country and prevalence of resistance                                                                              
  -------------------------------- ------ -------------------------------------- ------ ------ ------ ------ ------ ------- ------ --------- ------ ------- ------
  Ampicillin                       2002   55.7                                   45.0   43.0   13.0   49.9   \-     92.9    13.0   \-        77.0   19.0    \-
                                   2003   69.2                                   42.9   51.0   15.4   51.5   65.0   93.0    \-     \-        70.1   14.0    21.0
                                   2004   72.3                                   45.8   47.0   16.0   53.2   \-     \-      7.0    \-        72.2   22.0    4.2
                                                                                                                                                            
  Amoxicillin -- Clavulanic acid   2002   11.5                                   \-     \-     \-     2.7    \-     0.1     \-     58.0      1.0    \-      \-
                                   2003   4.4                                    3.9    \-     \-     9.2    24.0   1.0     \-     31.0      2.6    \-      0.0
                                   2004   0.7                                    0.6    \-     \-     2.0    \-     \-      \-     36.0      1.8    \-      0.0
                                                                                                                                                            
  Apramycin                        2002   6.6                                    17.0   12.0   \-     3.0    \-     \-      3.0    \-        23.0   \-      \-
                                   2003   13.2                                   9.1    16.0   \-     3.7    \-     \-      \-     \-        20.8   \-      \-
                                   2004   13.1                                   13.6   8.0    \-     3.3    \-     \-      \-     \-        13.0   \-      \-
                                                                                                                                                            
  Ceftiofur                        2002   1.6                                    0.0    \-     \-     0.1    \-     \-      0.0    \-        1.0    0.0     \-
                                   2003   2.2                                    0.0    \-     0.0    0.0    \-     \-      \-     \-        \-     0.0     0.0
                                   2004   0.7                                    0.0    \-     0.0    0.6    \-     \-      0.0    \-        3.6    \<1.0   \-
                                                                                                                                                            
  Chloramphenicol                  2002   49.2                                   31.0   \-     \-     \-     \-     \-      0.0    42.0      45.0   \-      \-
                                   2003   34.1                                   25.0   \-     3.1    \-     \-     \-      \-     49.0      35.1   \-      18.7
                                   2004   38.7                                   41.8   \-     7.0    \-     \-     \-      4.0    45.0      40.8   \-      38.3
                                                                                                                                                            
  Ciprofloxacin                    2002   3.3                                    0.0    8.0    4.0    4.7    \-     \-      0.0    76.0^a^   15.0   7.0     \-
                                   2003   1.1                                    0.0    2.0    1.5    6.2    22.0   \-      \-     38.0^a^   14.9   0.0     1.3
                                   2004   2.9                                    0.0    2.0    0.0    5.5    \-     \-      0.0    30.0^a^   14.2   6.0     0.0
                                                                                                                                                            
  Florfenicol                      2002   1.6                                    0.0    \-     \-     2.0    \-     \-      0.0    \-        4.0    0.6     \-
                                   2003   2.2                                    1.3    \-     1.5    1.2    \-     \-      \-     \-        7.1    0.0     \-
                                   2004   4.4                                    0.0    \-     0.0    0.9    \-     \-      0.0    \-        7.1    \-      \-
                                                                                                                                                            
  Gentamicin                       2002   4.9                                    14.0   \-     \-     5.6    \-     0.0     3.0    58.0      25.0   1.0     \-
                                   2003   1.1                                    6.5    \-     0.0    6.1    15.0   \-      \-     33.0      19.5   2.0     15.8
                                   2004   3.6                                    12.0   \-     0.0    5.5    \-     \-      0.0    45.0      19.5   0.0     12.7
                                                                                                                                                            
  Nalidixic acid                   2002   19.7                                   19.0   \-     \-     17.1   \-     0.0     0.0    85.0^b^   45.0   \-      \-
                                   2003   18.7                                   25.3   \-     21.5   \-     35.0   \<1.0   \-     \-        42.2   \-      \-
                                   2004   34.3                                   32.0   \-     13.0   \-     \-     \-      2.0    \-        33.7   \-      \-
                                                                                                                                                            
  Neomycin                         2002   14.8                                   36.0   11.0   \-     10.6   \-     0.0     0.0    \-        26.0   4.0     \-
                                   2003   2.2                                    31.2   19.0   3.1    11.8   48.0   0.0     \-     \-        24.7   6.0     12.2
                                   2004   1.5                                    35.0   11.0   7.0    10.9   \-     \-      2.0    \-        20.1   4.0     \-
                                                                                                                                                            
  Streptomycin                     2002   \-                                     77.0   \-     45.0   \-     \-     \-      54.0   79.0      73.0   33.0    \-
                                   2003   \-                                     66.3   \-     47.7   \-     92.0   \-      \-     60.0      73.4   32.0    \-
                                   2004   \-                                     77.4   \-     54.0   \-     \-     \-      47.0   64.0      74.0   28.0    \-
                                                                                                                                                            
  Sulphonamide                     2002   \-                                     77.0   \-     \-     \-     \-     \-      23.0   \-        82.0   \-      \-
                                   2003   \-                                     72.7   \-     33.8   \-     92.0   \-      \-     \-        74.7   \-      \-
                                   2004   \-                                     82.0   \-     51.0   \-     \-     \-      7.0    \-        76.3   \-      \-
                                                                                                                                                            
  Tetracycline                     2002   75.4                                   75.0   85.0   44.0   86.2   \-     \-      41.0   94.0      86.0   28.0    \-
                                   2003   80.2                                   72.7   83.0   46.2   84.7   86.0   \-      \-     91.0      86.4   23.0    57.8
                                   2004   77.4                                   91.0   82.0   51.0   82.6   \-     \-      24.0   98.0      87.0   27.0    57.4
                                                                                                                                                            
  Trimethoprim                     2002   \-                                     \-     \-     \-     \-     \-     \-      15.0   \-        63.0   \-      \-
                                   2003   \-                                     \-     \-     29.2   \-     \-     \-      \-     \-        72.1   \-      \-
                                   2004   \-                                     \-     \-     44.0   \-     \-     \-      7.0    \-        66.9   27.0    \-
                                                                                                                                                            
  Trimethoprim -- Sulphonamide     2002   67.2                                   38.0   52.0   38.0   65.1   \-     73.7    \-     \-        \-     21.0    \-
                                   2003   70.3                                   36.4   \-     \-     66.9   79.0   21.5    \-     \-        \-     \-      21.5
                                   2004   70.8                                   48.6   55.0   \-     66.4   \-     \-      \-     \-        \-     \-      \-

-: No data available, ^a^: enrofloxacin used, ^b^: flumequine used. B -- Belgium, DK -- Denmark, E -- England including Wales; F -- France; FIN -- Finland; LV -- Latvia; NL -- The Netherlands; N -- Norway; P -- Portugal; ES -- Spain; S -- Sweden; CH -- Switzerland.

###### 

Occurrence of antimicrobial resistance among *Escherichia coli*isolated from healthy pigs in different European countries.

  Antimicrobial agent             Year   Country and prevalence of resistance                                                                    
  ------------------------------- ------ -------------------------------------- ---- ------ ------ ------ ------ ---------- ------ ------ ------ ------
  Ampicillin                      2002   \-                                     62   10.9   \-     31.0   \-     25.5       5.9    \-     56.7   \-
                                  2003   \-                                     \-   22.7   \-     26.5   46.0   27.7 ^a^   \-     \-     68.4   3.0
                                  2004   6.0                                    \-   33.2   6.0    22.0   54.2   25.3       8.0    9.5    69.9   \-
                                                                                                                                                 
  Amoxicillin + Clavulanic acid   2002   \-                                     1    \-     \-     \-     \-     \-         \-     \-     2.4    \-
                                  2003   \-                                     \-   0.3    \-     \-     1.0    \-         \-     \-     0.7    0.3
                                  2004   0.0                                    \-   1.0    \-     \-     1.2    \-         \-     \-     0.0    \-
                                                                                                                                                 
  Apramycin                       2002   \-                                     4    0.3    \-     2.0    \-     \-         0.0    \-     5.9    \-
                                  2003   \-                                     \-   0.9    \-     9.1    \-     \-         \-     \-     4.2    0.0
                                  2004   1.8                                    \-   3.4    \-     4.0    \-     \-         \-     \-     4.9    \-
                                                                                                                                                 
  Ceftiofur                       2002   \-                                     1    0.0    \-     \-     \-     0.0        0.0    \-     0.0    \-
                                  2003   \-                                     \-   0.0    \-     \-     0.0    0.6 a      \-     \-     0.0    0.0
                                  2004   0.0                                    \-   0.0    0.0    \-     0.0    0.3        0.0    0.6    0.5    \-
                                                                                                                                                 
  Chloramphenicol                 2002   \-                                     33   3.7    \-     21.0   \-     9.4        0.5    \-     30.5   \-
                                  2003   \-                                     \-   6.7    \-     21.4   26.0   7.7 ^a^    \-     \-     37.9   0.7
                                  2004   3.7                                    \-   9.1    1.0    14.0   28.9   12.2       0.8    2.5    30.6   \-
                                                                                                                                                 
  Ciprofloxacin                   2002   \-                                     2    0.0    \-     0.0    \-     0.0        0.0    \-     1.7    \-
                                  2003   \-                                     \-   1.8    \-     0.0    1.0    0.0^a^     \-     \-     1.1    1.0
                                  2004   0.9                                    \-   0.0    0.0    1.0    5.4    0.0        0.0    2.5    3.3    \-
                                                                                                                                                 
  Florfenicol                     2002   \-                                     1    0.0    \-     1.0    \-     0.0        0.0    \-     0.7    \-
                                  2003   \-                                     \-   0.0    \-     2.0    \-     0.6^a^     \-     \-     2.1    0.0
                                  2004   0.0                                    \-   0.0    0.0    1.0    \-     0.0        0.0    2.0    2.2    \-
                                                                                                                                                 
  Gentamicin                      2002   \-                                     3    0.3    \-     0.0    \-     1.3        0.0    \-     4.8    \-
                                  2003   \-                                     \-   0.6    \-     3.1    2.0    1.3^a^     \-     \-     5.3    0.0
                                  2004   0.9                                    \-   3.4    0.0    0.0    1.2    0.3        0.0    0.6    7.7    \-
                                                                                                                                                 
  Nalidixic acid                  2002   \-                                     5    1.0    \-     5.0    \-     1.0        0.5    \-     12.8   \-
                                  2003   \-                                     \-   1.9    \-     7.1    8.0    0 ^a^      \-     \-     14.4   1.0
                                  2004   2.3                                    \-   3.4    1.0    3.0    6.6    1.7        0.0    6.4    20.8   \-
                                                                                                                                                 
  Neomycin                        2002   \-                                     0    3.0    \-     1.0    \-     1.3        0.5    \-     14.5   \-
                                  2003   \-                                     \-   5.7    \-     5.9    \-     3.2^a^     \-     \-     13.7   1.0
                                  2004   2.3                                    \-   15.8   1.0    5.0    \-     2.0        0.8    \-     11.5   \-
                                                                                                                                                 
  Streptomycin                    2002   \-                                     46   33.8   \-     65.0   \-     \-         20.8   \-     70.9   \-
                                  2003   \-                                     \-   43.9   \-     67.0   49.0   \-         \-     \-     72.3   13.0
                                  2004   54.4                                   \-   47.6   15.0   62.0   48.2   \-         33.6   34.7   66.1   \-
                                                                                                                                                 
  Sulphonamides                   2002   \-                                     73   23.2   \-     \-     \-     \-         10.7   \-     70.6   \-
                                  2003   \-                                     \-   30.6   \-     \-     51.0   \-         \-     \-     77.5   9.0
                                  2004   30.0                                   \-   46.6   12.0   \-     \-     52.7       12.0   15.9   73.2   \-
                                                                                                                                                 
  Tetracycline                    2002   \-                                     80   25.9   \-     89.0   \-     57.7       7.4    \-     91.0   \-
                                  2003   \-                                     \-   30.2   \-     81.2   66.0   69.7 ^a^   \-     \-     93.0   12.0
                                  2004   58.1                                   \-   43.8   16.0   86.0   81.0   63.9       9.6    31.6   95.6   \-
                                                                                                                                                 
  Trimethoprim                    2002   \-                                     68   6.1    \-     61.0   \-     43.0       4.8    \-     69.2   \-
                                  2003   \-                                     \-   13.6   \-     48.0   \-     43.9 ^a^   \-     \-     76.5   4.0
                                  2004   3.4                                    \-   \-     8.0    44.0   \-     5.7        4.0    1.0    66.7   \-
                                                                                                                                                 
  Trimethoprim + Sulphonamides    2002   \-                                     \-   \-     \-     \-     \-     41.6       \-     \-     \-     \-
                                  2003   \-                                     \-   \-     \-     \-     49.0   43.2 ^a^   \-     \-     \-     \-
                                  2004   \-                                     \-   49.0   \-     \-     47.6   43.9       \-     13     72.3   \-

-: No data available, ^a^: faeces. A -- Austria; B -- Belgium, DK -- Denmark, E -- England including Wales; F -- France; FIN -- Finland; I -- Italy; NL -- The Netherlands; N -- Norway; PL -- Poland; ES -- Spain; S -- Sweden.

Actinobacillus pleuropneumoniae
-------------------------------

Susceptibility data for *A. pleuropneumoniae*from infected pigs were obtained from five countries, which annually tested between 583 and 938 isolates (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). In general, nearly all of the isolates from Denmark showed low resistance to all drugs tested. In England (and Wales), resistance was observed which seemed to decrease over time for ampicillin (4.0% in 2002 to 2.0% in 2004) and ciprofloxacin (from 4.0%, in 2002 to 0.0% in 2004).

Streptococcus suis
------------------

Over the three-year period, 2,553 isolates were tested with the majority of these (1,809) isolated in 2003.

In general, a high level of resistance to tetracycline (48.0 -- 92.0%), trimethoprim -- sulphonamide (3.0 to 51.5%) and erythromycin (29.1 -- 75.0%) was observed in all participating countries. However, the number of isolates being resistant to penicillin differed between the countries. The isolates from England (and Wales), France and The Netherlands were susceptible to penicillin. In contrast, the resistance level for penicillin in Denmark, Poland and Portugal ranged from 0.9 to 13.0%.

Resistance to gentamicin was observed only in isolates from Poland and Portugal. All isolates from Portugal were completely resistant in 2004. There was a decrease in resistance to trimethoprim -- sulphonamide in France (from 22.4% in 2002 to 13.3% in 2004) and Poland (from 30.0% in 2002 to 14.4% in 2004). The frequency of resistance to trimethoprim -- sulphonamide in England (and Wales) (from 3.0% to 8.0%) and in The Netherlands (8.0%) were at the same level as in France and Poland in 2004. In contrast, the frequency of resistance to the same antimicrobial were considerable higher in Denmark (51.5%) compared to the other countries. Resistance to penicillin was detected in both Poland (8.1% in 2004) and Portugal.

Escherichia coli
----------------

Susceptibility data for *E. coli*isolated from diseased pigs were obtained from 12 countries (Table [4](#T4){ref-type="table"}). The 12 countries submitted susceptibility data for 2,053 -- 2,920 isolates annually (Table [1](#T1){ref-type="table"}).

In contrast to the other pathogens included in this study, a frequent occurrence of resistance was observed to several antimicrobial agents in several countries. However, the occurrence varied markedly between antimicrobials and countries but seemed to be very stable within countries over the three-year period.

A high level of resistance was observed for *E. coli*to tetracyclines (Sweden: 23.0% in 2003; Portugal: 98.0% in 2004), streptomycin (Sweden: 28.0% in 2004; Latvia: 92.0% in 2004), and ampicillin (Spain: 72.2% in 2004; The Netherlands: 93.0% in 2003). The isolates were susceptible or showed relatively low levels of resistance to ceftiofur (1.0% to 3.6% in Spain). In addition, resistance to florfenicol showed similar trends as ceftiofur varying from 4.0% to 7.1% in Spain 2003 -- 2004.

Susceptibility data for *E. coli*isolated from the gastro-intestinal tract of healthy pigs (indicator bacteria) were obtained from 11 countries (Table [5](#T5){ref-type="table"}). The 11 countries tested between 1,165 -- 2,041 isolates during the three years period.

In general, a lower frequency of resistance was observed compared to pathogenic strains. However, as with the pathogenic strains, the level of resistance appeared to increase for some antimicrobials (streptomycin, sulphonamides, tetracycline, trimethoprim and trimethoprim -- sulphonamide). Generally, the frequencies of resistance were higher in Belgium, Denmark, France, Italy, The Netherlands and Spain than in the other countries.

Discussion
==========

For each bacterial species a list of relevant antimicrobials was agreed upon but most laboratories provided data for different panels of antimicrobial agents. The same heterogeneity was observed in the breakpoints applied. We are aware that publishing data from multiple laboratories can be very difficult because there might be variations in methods used, interpretative criteria, etc. In the ideal world all laboratories would use the same methods and we could believe that data were directly comparable. However, since this unfortunately is not the case and there actually are major differences in the methods used we decided to ensure the comparability of the data by an external quality control system and only include data from laboratories and pathogens where the cut-off was met. This demonstrates an important problem in performing international monitoring based on data produced by routine diagnostic work using different panels, methods, equipment etc. \[[@B4],[@B5]\]. In addition, it shows a potential for future improvement of international monitoring based on comparable data as required by the Zoonoses Directive 2003/99/EC \[[@B6]\]. There is currently no mandatory international standard for antimicrobial testing at diagnostic laboratories in Europe or world-wide \[[@B4],[@B5]\].

The design used in this study has certain limitations due to the lack of standardisation of the sample selection and microbiological procedures used for isolation, but we believe that this heterogeneity had only a minor effect on the results. The summary data originate from samples submitted to diagnostic laboratories in the different countries. It is believed, that well-standardised and international recognised methods have been used as the laboratories all are appointed as national reference laboratories. The laboratories have categorized the samples mainly as \"diagnostic samples originating from cases of infection\". The *S. suis*and *A. pleuropneumoniae*isolates described in this study were mainly associated with pleuritis whereas *E. coli*(clinical isolates) were mostly associated with diarrhoea.

To gain reliable and comparable susceptibility data, an EQAS program was conducted annually for all organisms described in the ARBAO II project including *S. suis*, *A. pleuropneumoniae*and *E. coli*. The results show that despite the lack of harmonization and standardization of the susceptibility tests used in the different diagnostic laboratories, the results of the interpret test results were comparable as to define the sensitivity category.

Actinobacillus pleuropneumoniae
-------------------------------

A rise in frequencies of resistance especially to ampicillin, fluoroquinolones and tetracyclines have been reported from other countries previously \[[@B7]-[@B10]\]. Especially the reports from Taiwan and Korea indicate a national development of *A. pleuropneumoniae*resistant to multiple antimicrobials such as ampicillin, chloramphenicol, flumequine, nalidixic acid, streptomycin, sulphonamide -- trimethoprim and tetracycline \[[@B7],[@B9]\].

The data from our survey may be used as guideline for empiric treatment in countries with no or low prevalence of resistance but in the future, the use of antimicrobials should be based on resistance data obtained from clinical cases.

Penicillin and tetracyclines have been reported as the most frequently used drugs for treatment of porcine respiratory tract infections \[[@B11],[@B12]\]. With the frequent occurrence of tetracycline resistance, this drug should probably not be used as a first choice unless susceptibility test results have shown susceptibility. In countries with no or low level of resistance to penicillin this drug should be considered as the first choice for treatment of infections with *A. pleuropneumoniae*.

Another possibility is the use of ciprofloxacin although resistance has also emerged for this class of drugs in some countries. Therefore, the occurrence of resistance and trends in resistance should be monitored carefully for *A. pleuropneumoniae*. The results obtained should be made available for veterinarians for an effective usage of these drugs and to minimise the selection pressure for antimicrobial resistance.

Streptococcus suis
------------------

The resistance levels observed to trimethoprim -- sulphonamide is comparable to previous reports from Denmark \[[@B13]\], France \[[@B14]\] and Japan \[[@B15]\]. The occurrence of penicillin resistance reported from Denmark, Poland and Portugal is surprising, since penicillin resistance in streptococci is generally rare. Five isolates from Poland were re-tested at the National Food Institute, Technical University of Denmark. The MIC values found in Poland were confirmed (data not shown). The genetic mechanisms are not finally elucidated but variations in the gene coding for the penicillin binding proteins have been found in isolates from both Denmark and Poland (unpublished results). Thus, these results could indicate that penicillin resistance is emerging in *S. suis*. This should be followed closely.

Escherichia coli
----------------

The occurrence of resistance in *E. coli*varied markedly between antimicrobials and countries but seemed to be very stable within countries over the three year period. We recommend that the choice of empirical treatment for *E. coli*infections based on the sparse data in this study needs to be adapted according to the resistance situation in the individual countries. In contrast to the general pattern of susceptibility observed in *A. pleuropneumoniae*and *S. suis*, resistance profiles of *E. coli*showed a marked geographic variation. The susceptibility results in *E. coli*from other studies support the results obtained in this study \[[@B16]-[@B19]\]. As a consequence only a limited number of antimicrobial agents are useful for empirical treatment of infections in pigs caused by this bacterium. With the emergence of resistance to ciprofloxacin the options available for treatment of intestinal infections are restricted to colistin based on the selection of drugs included in this study. However, due to the poor knowledge on resistance against this antibiotic and the methodological difficulties in testing susceptibility with disk diffusion methods, the actual level of resistance against colistin is largely unknown \[[@B20],[@B21]\].

In general, the levels of resistance were lower in *E. coli*from healthy pigs than in *E. coli*strains isolated from diseased animals. This is partly due to a sampling bias of the isolates from clinical cases which probably had a major impact on the internal and external validity of results. In fact, diagnostic specimens are mostly sent to the laboratory following severe illness, widespread disease or when therapeutic failures occur. The level of resistance might therefore be higher due to previous (unsuccessful) treatment compared with isolates from healthy animals. In such cases the laboratory receives a subset of pathogens that often present resistance at a higher level than those from the general population of pathogens, because the animals may have already been treated with first-line antimicrobials before sampling. However, the data clearly show the occurrence of resistance in indicator bacteria and highlight their potential role as an ordinary resistance reservoir as a consequence of the use of antimicrobials in livestock.

Conclusion
==========

Occurrence of resistance to several antimicrobial agents was observed for *E. coli*and in some cases also for *S. suis*. This may reflect differences in the antimicrobial availability, treatment procedures, and animal husbandry practices between the different countries. In addition, the study suggests that the choice of substances used for the treatment of specific infections in animals has to be based on knowledge of the local pattern of resistance. In the future, the data from monitoring programs and resistance studies should be taken into account for the usage of antimicrobials in veterinary medicine.
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